Michael Schmitz
Stock Analyst at Guggenheim
(3.05)
# 1,215
Out of 5,182 analysts
8
Total ratings
71.43%
Success rate
77.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $17.06 | -70.69% | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $27.65 | +55.52% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $43.99 | +2.30% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $96.29 | -14.84% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $11.37 | +251.80% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.15 | - | 1 | Jan 3, 2023 | |
| APC ARKO Petroleum | Initiates: Buy | $85 | $18.30 | +364.48% | 1 | Dec 19, 2016 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $17.06
Upside: -70.69%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $27.65
Upside: +55.52%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $43.99
Upside: +2.30%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $96.29
Upside: -14.84%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $11.37
Upside: +251.80%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
ARKO Petroleum
Dec 19, 2016
Initiates: Buy
Price Target: $85
Current: $18.30
Upside: +364.48%